TOG Review (RCOG Journal)
MRCOG Part 2
Gynaecological Problems
Menopause care
Key Statistics
- 5–7 yrs — Average duration of menopausal symptoms
- 2–4× — ↑Depression rate, age 42–52
- 70% — ↓Flushes at 12WK, NK3 antagonist
Don't-miss facts
-
Bio-identical hormones are NOT an evidence-based "alternative" to HRT
-
Only clonidine and NK3 antagonists are licensed for vasomotor symptoms; NK3 antagonists (fezolinetant/elinzanetant) ↓flushes up to 70% by 12 weeks but are not yet NHS-prescribable and need LFT monitoring (2–3% stop for ↑transaminases)
-
Gabapentin only works for flushes at 900 mg/day (300 mg = no benefit); pregabalin 150 mg BD ↓flushes 71%
-
Sertraline, duloxetine (mod-high dose), paroxetine, fluoxetine ↓tamoxifen efficacy – prefer citalopram or venlafaxine in tamoxifen users
-
Ginseng and possibly black cohosh/milk thistle/sage are oestrogenic – caution/avoid in hormone-sensitive cancer
-
Vitamin E, omega-3, and high-dose (≥1000 mg) turmeric all reduce tamoxifen's chemopreventive effect
-
GSM in AI-treated breast cancer survivors: manage non-hormonally first; DHEA/low-dose vaginal estrogen only if severe and after individualised MDT discussion
-
Trial each alternative for 8–12 weeks before stopping/switching; review prescribables at 3 & 6 months
Licensed vs off-label vasomotor drugs
Licensed: clonidine, NK3 antagonists Off-label: SSRIs/SNRIs, gabapentin, pregabalin, oxybutynin, mirtazapine
Avoid/caution with tamoxifen or hormone-sensitive cancer
Ginseng St John's wort Milk thistle Sage High-dose turmeric Vitamin E/omega-3 (high dose)
Sertraline/duloxetine/paroxetine/fluoxetine
Abbreviation Key
- HRT — hormone replacement therapy
- iCR — isopropanolic black cohosh
- GSM — genitourinary syndrome of menopause
- HA — hyaluronic acid
- DHEA — dehydroepiandrosterone
- FSFI — Female Sexual Functioning Index
- AI — aromatase inhibitor
- ER — estrogen receptor
- CBT — cognitive behavioural therapy
- GLP-1 — glucagon-like peptide-1 (receptor agonist)
- SSRI — selective serotonin reuptake inhibitor
- PARP — poly-ADP ribose polymerase
- SNRI — selective norepinephrine reuptake inhibitor
- ADHD — attention deficit hyperactivity disorder
- MDT — multidisciplinary team
- NICE — National Institute for Health and Care Excellence
- NK3 — neurokinin 3 (receptor antagonist)
Source: Menopause care: alternatives to hormone replacement therapy. The Obstetrician & Gynaecologist 2025;27:308–320. doi:10.1111/tog.70010
MRCOG AI is an independent educational tool. It is not affiliated with, endorsed by, or connected to the Royal College of Obstetricians and Gynaecologists (RCOG).